Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citiolone SCHEMBL364495 | 1.00 | CYP1A2 (0.60) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| Citiolone SCHEMBL3157776 | 0.98 | CYP1A2 (0.58) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL4587843 | 0.85 | HPGD (0.58) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL14521500 | 0.82 | CYP1A2 (0.73) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL21007472 | 0.82 | CYP1A2 (0.73) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL15976421 | 0.82 | USP2 (0.63) | CYP1A2USP2POLB | |
| SCHEMBL16257700 | 0.82 | HPGD (0.56) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL12505245 | 0.82 | ALDH1A1 (0.62) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL15185176 | 0.80 | ALDH1A1 (0.56) | CYP1A2USP2ALDH1A1POLBMEN1 | |
| SCHEMBL11256738 | 0.80 | ALDH1A1 (0.56) | CYP1A2USP2ALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1704167-B1 | A METHOD TO MAKE A PEPTIDE-CARRIER CONJUGATE WITH A HIGH IMMUNOGENICITY | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-01-12 | — | — | EP | claimed |
| WO-2010078376-A2 | FC-SPECIFIC POLYMER-CONJUGATED ANTIBODIES AND THEIR DIAGNOSTIC USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | claimed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | claimed |
| EP-1893241-A2 | FLUORESCENT NANOPARTICLES CONJUGATED TO ANTIBODIES VIA A PEG LINKER | Ventana Medical Systems, Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| EP-1877101-A2 | ENZYMES CONJUGATED TO ANTIBODIES VIA A PEG HETEROBIFUCTIONAL LINKER | Ventana Medical Systems, Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20060246524-A1 | Nanoparticle conjugates | VENTANA MEDICAL SYSTEMS, INC. | 2006-11-02 | — | — | US | claimed |
| WO-2006116742-A2 | FLUORESCENT NANOPARTICLES CONJUGATED TO ANTIBODIES VIA A PEG LINKER | VENTANA MEDICAL SYSTEMS, INC. (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116628-A2 | ENZYMES CONJUGATED TO ANTIOBODIES VIA A PEG HETEROBIFUCTIONAL LINKER | VENTANA MEDICAL SYSTEMS, INC. (US) | 2006-11-02 | — | — | WO | claimed |
| US-20060246523-A1 | Antibody conjugates | VENTANA MEDICAL SYSTEMS, INC. | 2006-11-02 | — | — | US | claimed |
| EP-0787228-B1 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMW SCIENT IND RES ORG (AU) | 2003-01-02 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0340198-B1 | Immunoassay for the detection of alpha-haloacetamides | MONSANTO CO (US) | 1994-11-30 | — | — | EP | claimed |
| EP-0489061-A4 | RADIO-LABELLED ANTIBODIES FOR IMAGING | — | 1992-10-14 | — | — | EP | claimed |
| EP-0489061-A1 | RADIO-LABELLED ANTIBODIES FOR IMAGING | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 1992-06-10 | — | — | EP | claimed |
| EP-0161188-B1 | COVALENTLY-MODIFIED BACTERIAL POLYSACCHARIDES, STABLE COVALENT CONJUGATES OF SUCH POLYSACCHARIDES AND IMMUNOGENIC PROTEINS WITH BIGENERIC SPACERS, AND METHODS OF PREPARING SUCH POLYSACCHARIDES AND CONJUGATES AND OF CONFIRMING COVALENCY | MERCK & CO. INC. (US) | 1991-04-03 | — | — | EP | claimed |
| WO-1991002547-A1 | RADIO-LABELLED ANTIBODIES FOR IMAGING | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 1991-03-07 | — | — | WO | claimed |
| EP-0057140-B1 | THIOLATED POLYPEPTIDIC COMPOUND FROM A TETANIC TOXIN FRAGMENT, PROCESS FOR ITS PRODUCTION AND ITS APPLICATIONS | INSTITUT PASTEUR (FR) | 1985-07-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246524-A1 | Nanoparticle conjugates | EPCAM, MUC1, CD63 | CYP1A2 3404/4885USP2 941/4885ALDH1A1 248/4885 |
| US-20060246523-A1 | Antibody conjugates | BCR, CD2BP2, EPCAM | CYP1A2 1583/4885USP2 1965/4885ALDH1A1 169/4885 |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | ACHE, S100P, P2RX3 | CYP1A2 1708/4885USP2 2247/4885ALDH1A1 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.